EXAS Exact Sciences
- 51.950
- -1.390-2.61%
- 51.950
- 0.0000.00%
Exact Sciences News
Most Attractive Short-term Overwriting Stocks for June Expiration - Goldman
Goldman Sachs analysts identified short-term overwriting opportunities in large-cap, high implied volatility stocks that do not have earnings events.
Piper Sandler Keeps Their Buy Rating on Exact Sciences (EXAS)
Exact Sciences Corporation (NASDAQ:EXAS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Exact Sciences Corp (EXAS) Q1 2024 Earnings: Revenue Growth Amidst Increased Net Loss
Exact Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences' Oncotype DX Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients
LONDON--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK's National Institute for Health and Care Excellence (NICE) has recomme
Analysts Offer Insights on Healthcare Companies: Certara (CERT), Exact Sciences (EXAS) and AbCellera Biologics (ABCL)
Optimistic Outlook for Exact Sciences: Overcoming Challenges With Growth Initiatives and New Product Potential
Canadian Investment Banking Group: Maintaining the Exact Sciences (EXAS.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $90.00 to $85.00.
Canadian Investment Banking Group: Maintaining the Exact Sciences (EXAS.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $90.00 to $85.00.
Exact Sciences Is Maintained at Buy by Citigroup
Exact Sciences Is Maintained at Buy by Citigroup
Exact Sciences Price Target Cut to $80.00/Share From $100.00 by Citigroup
Exact Sciences Price Target Cut to $80.00/Share From $100.00 by Citigroup
Citigroup Maintains Buy on Exact Sciences, Lowers Price Target to $80
Citigroup analyst Patrick Donnelly maintains Exact Sciences (NASDAQ:EXAS) with a Buy and lowers the price target from $100 to $80.
Exact Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 45.92% Citigroup $100 → $80 Maintains Buy 04/03/2024 82.4% Citigroup → $100 Maintains Buy 02/22
Stocks Rebound As Rising Jobless Claims Sustain Rate-Cut Hopes, Dollar Falls, Gold Rallies: What's Driving Markets Thursday?
Wall Street is seeing a day of gains as all major indices traded in the green around noon in New York, driven by a surprising uptick in unemployment claims prompting speculation over Federal Reserve i
Exact Sciences Corporation (NASDAQ:EXAS) Q1 2024 Earnings Call Transcript
Unusual Options Activity: APA, WBD and Others Attract Market Bets, APA V/OI Ratio Reaches 1193.6
EST May 9th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.O
These Stocks Are Moving the Most Today: Roblox, AppLovin, Duolingo, Exact Sciences, SolarEdge, and More -- Barrons.com
By Joe Woelfel and Emily Dattilo Stocks were trading higher on Thursday, as investors digested more earnings reports in a quieter week for macroeconomic data. These stocks were moving on Thursday:
Exact Sciences (EXAS) Q1 Revenues Rise Y/Y, Gross Margin Down
Analysts' Top Healthcare Picks: US Physical Therapy (USPH), Exact Sciences (EXAS)
Research Alert: CFRA Retains Buy Opinion On Shares Of Exact Sciences Corporation
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lower our target to $65 from $73 base
Analysis
Price Target
No Data
